Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


12 julio 2012

FDA Warns Of Potential For Catheter Entrapment With ev3 s Onyx Liquid Embolic System

Medlatest

The FDA has issued a warning notice about a potential problem with Covidien subsidiary eV3′s Onyx Liquid Embolic System. Rather than recalling the device it seems issuing a warning and modifying instructions for use to raise awareness of the risk of the catheter device becoming entrapped in brain tissues is deemed adequate

09 julio 2012

Weekend Effect for Stroke Also True in U.K.

MEDPAGE TODAY. John Gever, Senior Editor

Stroke patients admitted to British hospitals on weekends were less likely to receive recommended treatment and had worse outcomes than those treated on weekdays, researchers said.

09 julio 2012

Hormonal treatment associated with better test performance after stroke

Neuro NEWS

Stroke patients treated who received hormonal treatment, combined with rehabilitation, performed better on functioning and reasoning tests than patients who received rehabilitative therapy alone, a new clinical study from Italy shows. The results of this study were presented at the Endocrine Society s 94th Annual Meeting in Houston, USA.

06 julio 2012

NeuroSigma receives global quality control certification for its external Trigeminal Nerve Stimulation

Neuro NEWS

NeuroSigma announced that it received ISO 13485: 2003 certification, indicating that it operates a Quality Management System for the design, manufacturing and distribution of its external Trigeminal Nerve Stimulation (eTNS) system for the treatment of neurological and neuropsychiatric disorders. This certification is an important first step in a two-step process towards CE mark approval in the European Union.

02 julio 2012

MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms

MDT Medical Design Tecnology

MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, today announced that enrollment has begun in the Hydrogel Endovascular Aneurysm Treatment (HEAT) clinical trial, a study of the use of coiling technologies to treat intracranial aneurysms. This prospective, randomized, international multicenter trial is designed to compare clinical outcomes in patients treated with the new generation of the MicroVention hydrogel coils to those treated with bare platinum coils. The HEAT trial will enroll up to 600 subjects from approximately 30 sites around the world.

02 julio 2012

NeuroSigma Receives Global Quality Control Certification

MDT Medical Design Tecnology. PRNewswire

Today NeuroSigma, Inc., a Los Angeles-based medical device company, announced that it received ISO 13485: 2003 certification, indicating that it operates a Quality Management System for the design, manufacturing and distribution of its external Trigeminal Nerve Stimulation (eTNS™) system for the treatment of neurological and neuropsychiatric disorders. This certification is an important first step in a two-step process towards CE Mark approval in the European Union.

28 junio 2012

FDA approves trabecular micro-bypass stent

Modern Medicine. Ophthalmology Times Staff Reports

FDA approval has been granted for a trabecular micro-bypass stent (iStent, Models GTS100R/GTS100L; Glaukos), making the device the first ab interno glaucoma implant to be approved in the United States, according to the company.

26 junio 2012

TPA Safe in Stroke Patients on Warfarin

MEDPAGE TODAY. Michael Smith, North American Correspondent

Patients who were taking warfarin were no more likely to develop symptomatic intracranial hemorrhage after treatment with intravenous tissue plasminogen activator (tPA) than those not on the anticoagulant, a large observational study showed. Nor was there an increased risk of serious systemic hemorrhage, any tPA complications, or in-hospital mortality, according to Eric Peterson, MD, of the Duke Clinical Research Institute, and colleagues.

26 junio 2012

Hormone May Aid Stroke Recovery

MEDPAGE TODAY. Charles Bankhead, Staff Writer

Stroke survivors had significantly better functional and cognitive outcomes when they received a nitric oxide-inducing hormone in addition to rehabilitation, Italian investigators reported. At 20 days, patients who received porcine-derived relaxin showed significantly better recovery of global and cognitive function (P=0.001 and P=0.002, respectively), but not daily activities, as compared with patients randomized to rehabilitation alone.

25 junio 2012

Statins Equally Effective in Men and Women

MEDPAGE TODAY. Crystal Phend, Senior Staff Writer

Both sexes gain from statins for secondary prevention of cardiovascular events, a meta-analysis found, though pooling enough data to prove that there is a statistically significant benefit in women appears to be a challenge. Both sexes saw a similar, significant overall cardiovascular benefit from the lipid-lowering drugs in high-quality clinical trials, Jose Gutierrez, MD, MPH, of Columbia University in New York City, and colleagues reported.

18 junio 2012

Mental Distress Linked to Stroke Mortality

MEDPAGE TODAY. Crystal Phend, Senior Staff Writer

Individuals scoring higher on a measure of general mental health had an increased risk of stroke mortality, a population-based study showed. Psychological distress predicted a significant 66% elevated risk of death from cerebrovascular disease, Mark Hamer, PhD, of the University College London, and colleagues found.

18 junio 2012

Penumbra Inc. Launches the New MAX™ System Reperfusion Catheters for Acute Ischemic Stroke Patients

BioSpace. BUSINESS WIRE

The Penumbra System® family of aspiration thrombectomy devices now includes the MAX System of Reperfusion Catheters for removal of clots in patients experiencing acute ischemic stroke. The MAX System neuro-interventional devices offer a fast, simplified cerebral thrombectomy procedure with single-operator, over-the-wire delivery without the need for a large proximal balloon guide.

18 junio 2012

La ansiedad y la depresión podrían elevar el riesgo de ACV. Las pruebas para el distrés psicológico podrían salvar las vidas de los pacientes, señalan investigadores

MedlinePlus. Mary Elizabeth Dallas . HealthDay News

Las personas que sufren de ansiedad, depresión, insomnio y otras formas de distrés psicológico están en mayor riesgo de muerte por accidente cerebrovascular (ACV), según un estudio reciente. Investigadores del Colegio Universitario de Londres apuntaron que el distrés psicológico afecta a entre 15 y 20 por ciento de la población general. Investigaciones anteriores han relacionado a estas afecciones mentales comunes con la enfermedad de la arteria coronaria, pero no se ha establecido una asociación con el ACV y otras enfermedades cardiovasculares.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.